| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival in multiple myeloma and the impact of novel therapies.
|
Blood
|
2007
|
12.70
|
|
2
|
Review of 1027 patients with newly diagnosed multiple myeloma.
|
Mayo Clin Proc
|
2003
|
9.96
|
|
3
|
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
|
J Clin Oncol
|
2005
|
6.98
|
|
4
|
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
|
Blood
|
2005
|
5.82
|
|
5
|
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
|
Lancet Oncol
|
2009
|
5.73
|
|
6
|
Clinical and biologic implications of recurrent genomic aberrations in myeloma.
|
Blood
|
2003
|
4.67
|
|
7
|
Genetics and cytogenetics of multiple myeloma: a workshop report.
|
Cancer Res
|
2004
|
4.54
|
|
8
|
POEMS syndrome: definitions and long-term outcome.
|
Blood
|
2002
|
4.35
|
|
9
|
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
3.88
|
|
10
|
Narrative review: the systemic capillary leak syndrome.
|
Ann Intern Med
|
2010
|
3.71
|
|
11
|
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
|
J Clin Oncol
|
2004
|
3.43
|
|
12
|
Genomic abnormalities in monoclonal gammopathy of undetermined significance.
|
Blood
|
2002
|
3.34
|
|
13
|
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
|
J Clin Oncol
|
2006
|
3.20
|
|
14
|
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
|
Blood
|
2004
|
2.97
|
|
15
|
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
|
Mayo Clin Proc
|
2006
|
2.88
|
|
16
|
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
|
Mayo Clin Proc
|
2009
|
2.86
|
|
17
|
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
|
Blood
|
2003
|
2.67
|
|
18
|
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
|
J Clin Oncol
|
2002
|
2.63
|
|
19
|
Clinical course of patients with relapsed multiple myeloma.
|
Mayo Clin Proc
|
2004
|
2.62
|
|
20
|
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
|
Mayo Clin Proc
|
2007
|
2.55
|
|
21
|
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.
|
Blood
|
2005
|
2.54
|
|
22
|
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
|
J Clin Oncol
|
2009
|
2.50
|
|
23
|
Current therapy for multiple myeloma.
|
Mayo Clin Proc
|
2002
|
2.47
|
|
24
|
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
|
Blood
|
2011
|
2.45
|
|
25
|
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
|
Mayo Clin Proc
|
2007
|
2.34
|
|
26
|
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
|
Blood
|
2003
|
2.12
|
|
27
|
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
|
Blood
|
2003
|
2.12
|
|
28
|
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
|
Blood
|
2009
|
2.12
|
|
29
|
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
|
Blood
|
2006
|
2.06
|
|
30
|
Sharply increased serum free light-chain concentrations after treatment for multiple myeloma.
|
Clin Chem
|
2010
|
2.05
|
|
31
|
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.
|
J Clin Oncol
|
2013
|
2.01
|
|
32
|
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
|
Blood
|
2004
|
2.01
|
|
33
|
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
|
Mayo Clin Proc
|
2009
|
1.96
|
|
34
|
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.
|
Blood
|
2006
|
1.95
|
|
35
|
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
|
Blood
|
2006
|
1.94
|
|
36
|
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.
|
Blood
|
2005
|
1.87
|
|
37
|
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
|
J Clin Oncol
|
2012
|
1.87
|
|
38
|
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
|
Blood
|
2009
|
1.86
|
|
39
|
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience.
|
Mayo Clin Proc
|
2010
|
1.80
|
|
40
|
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
|
Cancer Res
|
2002
|
1.79
|
|
41
|
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
|
Mayo Clin Proc
|
2003
|
1.72
|
|
42
|
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
|
Blood
|
2008
|
1.68
|
|
43
|
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.
|
Blood
|
2005
|
1.66
|
|
44
|
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
|
Blood
|
2002
|
1.63
|
|
45
|
Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome).
|
Blood
|
2012
|
1.58
|
|
46
|
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
|
Clin Cancer Res
|
2002
|
1.57
|
|
47
|
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
|
Nephrol Dial Transplant
|
2009
|
1.56
|
|
48
|
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.
|
Mayo Clin Proc
|
2011
|
1.53
|
|
49
|
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.
|
Blood
|
2006
|
1.50
|
|
50
|
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
|
Haematologica
|
2005
|
1.49
|
|
51
|
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.
|
Amyloid
|
2003
|
1.47
|
|
52
|
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
|
Blood
|
2011
|
1.46
|
|
53
|
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
|
Exp Hematol
|
2006
|
1.42
|
|
54
|
Appraisal of immunoglobulin free light chain as a marker of response.
|
Blood
|
2008
|
1.38
|
|
55
|
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions.
|
Blood
|
2002
|
1.35
|
|
56
|
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
|
Mayo Clin Proc
|
2010
|
1.34
|
|
57
|
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
|
Mayo Clin Proc
|
2010
|
1.32
|
|
58
|
Cardiac amyloidosis: a practical approach to diagnosis and management.
|
Am J Med
|
2011
|
1.31
|
|
59
|
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
|
Cancer Genet Cytogenet
|
2006
|
1.27
|
|
60
|
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
|
Blood
|
2004
|
1.26
|
|
61
|
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
|
Blood
|
2004
|
1.24
|
|
62
|
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).
|
Leuk Lymphoma
|
2004
|
1.21
|
|
63
|
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
|
Blood
|
2009
|
1.18
|
|
64
|
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
|
Cancer
|
2004
|
1.14
|
|
65
|
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
|
Cancer
|
2006
|
1.12
|
|
66
|
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
|
Am J Hematol
|
2011
|
1.11
|
|
67
|
Clinical implication of centrosome amplification in plasma cell neoplasm.
|
Blood
|
2005
|
1.11
|
|
68
|
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
|
Br J Haematol
|
2006
|
1.11
|
|
69
|
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
|
Am J Hematol
|
2010
|
1.10
|
|
70
|
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
|
Blood
|
2012
|
1.08
|
|
71
|
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.
|
Blood
|
2005
|
1.08
|
|
72
|
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
|
Exp Hematol
|
2005
|
1.06
|
|
73
|
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
|
J Clin Oncol
|
2005
|
1.05
|
|
74
|
Anti-CD20 monoclonal antibody therapy in multiple myeloma.
|
Br J Haematol
|
2008
|
1.05
|
|
75
|
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
|
Cancer
|
2006
|
1.05
|
|
76
|
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma.
|
Blood
|
2004
|
1.05
|
|
77
|
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
|
Clin Cancer Res
|
2007
|
1.04
|
|
78
|
Prognostic value of angiogenesis in solitary bone plasmacytoma.
|
Blood
|
2002
|
1.04
|
|
79
|
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
|
Clin Cancer Res
|
2008
|
1.02
|
|
80
|
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis.
|
Blood
|
2002
|
1.02
|
|
81
|
Trends and outcomes of modern staging of solitary plasmacytoma of bone.
|
Am J Hematol
|
2012
|
1.01
|
|
82
|
Infection and killing of multiple myeloma by adenoviruses.
|
Hum Gene Ther
|
2010
|
0.98
|
|
83
|
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
|
Ann Hematol
|
2010
|
0.96
|
|
84
|
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
|
Blood
|
2011
|
0.95
|
|
85
|
Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.94
|
|
86
|
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
|
Haematologica
|
2009
|
0.93
|
|
87
|
Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.
|
J Interferon Cytokine Res
|
2006
|
0.91
|
|
88
|
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
|
Blood
|
2011
|
0.90
|
|
89
|
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.
|
Exp Hematol
|
2008
|
0.90
|
|
90
|
Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression.
|
Cancer Genet Cytogenet
|
2002
|
0.89
|
|
91
|
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
|
Br J Haematol
|
2003
|
0.85
|
|
92
|
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
|
Am J Hematol
|
2010
|
0.85
|
|
93
|
A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
|
Biol Blood Marrow Transplant
|
2009
|
0.85
|
|
94
|
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.
|
Br J Haematol
|
2011
|
0.83
|
|
95
|
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.
|
Leuk Res
|
2009
|
0.83
|
|
96
|
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis.
|
Haematologica
|
2008
|
0.83
|
|
97
|
Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.
|
Mayo Clin Proc
|
2010
|
0.83
|
|
98
|
Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
|
Br J Haematol
|
2009
|
0.81
|
|
99
|
Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma.
|
Clin Chem
|
2007
|
0.79
|
|
100
|
The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).
|
Blood Rev
|
2009
|
0.78
|
|
101
|
Bone marrow angiogenesis and circulating plasma cells in multiple myeloma.
|
Br J Haematol
|
2003
|
0.78
|
|
102
|
Immunoglobulin D amyloidosis: a distinct entity.
|
Blood
|
2011
|
0.78
|
|
103
|
Bone marrow angiogenesis in multiple myeloma: effect of therapy.
|
Br J Haematol
|
2002
|
0.78
|
|
104
|
Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
|
Am J Hematol
|
2004
|
0.77
|
|
105
|
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.
|
Cancer
|
2009
|
0.76
|
|
106
|
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.
|
Blood
|
2011
|
0.75
|
|
107
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
108
|
Angiogenesis in Waldenstrom's macroglobulinemia.
|
Semin Oncol
|
2003
|
0.75
|
|
109
|
Clinical impact of discordance in serum albumin measurements on myeloma international staging system.
|
J Clin Oncol
|
2008
|
0.75
|